Global Market Insights Inc.는 최고의 전략적 가치를 제공하도록 설계된 최첨단 비즈니스 인텔리전스(BI) 플랫폼인 GMIPulse를 제공하고 있으며, GMIPulse는 종합적이고 세분화된 시장 데이터, 경쟁 환경 분석, 산업 생태계에 대한 상세한 정보를 제공하며, 고객의 고유한 니즈에 맞게 맞춤화할 수 있는 적응력이 뛰어난 구독 서비스를 제공합니다. 이 플랫폼은 모든 시장 조사 요구 사항을 충족하고 최신 트렌드와 기술 발전에 앞서 나갈 수 있도록 보장합니다.
의료 산업은 기술 발전, 규제 변화, 혁신적인 치료 및 서비스에 대한 수요 증가로 인해 빠르게 변화하고 있으며, GMIPulse는 다음과 같은 의료 산업의 주요 부문에 대한 심층적인 통찰력을 제공합니다.
분석기기 시장은 2023년부터 2030년까지 연평균 6.5%의 성장률을 보일 것으로 예상되며, 이는 고급 진단 도구 및 연구용 용도에 대한 수요 증가에 힘입어 성장할 것으로 전망됩니다. 주요 부문으로는 크로마토그래피, 분광학, 분자 분석 등이 있습니다. 정밀의료와 유전체학의 부상으로 인해 고정밀 분석기기에 대한 수요가 크게 증가하고 있습니다.
생명공학 시장은 유전공학, 바이오 의약품, 세포 및 유전자 치료의 발전에 힘입어 2023년부터 2030년까지 7.8%의 연평균 성장률(CAGR)로 견조한 성장을 보일 것으로 예상됩니다. 주요 시장으로는 유전체학, 단백질학, 바이오프로세스가 있으며, CRISPR 기술과 개인 맞춤형 의료의 출현이 시장 성장을 가속하는 주요 요인으로 작용할 것입니다.
약물-기기 복합 제품 시장은 만성질환 유병률 증가와 혁신적인 약물 전달 시스템에 대한 수요에 힘입어 2023년부터 2030년까지 연평균 8.1%의 성장률을 보일 것으로 예상됩니다. 대표적인 예로는 약물 용출 스텐트, 경피 패치, 흡입기 등이 있습니다. 의약품과 의료기기의 조합에 스마트 기술을 통합하여 환자의 순응도와 치료 결과를 개선하고 있습니다.
의료 IT 시장은 전자의무기록(EHR), 원격의료, 의료정보교환(HIE) 도입 증가로 인해 2023년부터 2030년까지 연평균 9.4%의 성장률을 보일 것으로 예상됩니다. 주요 분야로는 임상 정보학, 의료용 분석, 사이버 보안 등이 있습니다. '가치 기반 의료(value-based care)로의 전환과 상호운용성의 필요성이 시장을 주도하는 중요한 트렌드입니다.
의료기기 시장은 기술 발전과 고령화 추세에 힘입어 2023년부터 2030년까지 연평균 5.9%의 성장률을 나타낼 것으로 예상됩니다. 주요 분야로는 영상 진단 기기, 수술 기기, 웨어러블 기기 등이 있으며, AI 기반 진단 도구, 최소 침습 수술 기기 등의 혁신이 환자 치료에 변화를 가져오고 있습니다.
의료 서비스 시장은 전문 의료 서비스 및 재택치료에 대한 수요 증가에 힘입어 2023년부터 2030년까지 6.2%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 주요 부문으로는 원격 의료, 외래 의료, 재활 서비스 등이 있습니다. 예방 의료와 만성 질환 관리에 대한 관심이 높아지면서 의료 서비스 전망이 재편되고 있습니다.
의약품 시장은 2023년부터 2030년까지 6.8%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 혁신적인 의약품에 대한 수요 증가와 생물학적 제제 및 바이오시밀러의 부상으로 시장 성장을 가속하는 요인으로 작용하고 있습니다. 주요 시장으로는 종양, 면역질환, 희귀질환 등이 있습니다. 새로운 치료법과 정밀의료의 발전은 시장 성장에 영향을 미치는 주요 동향입니다.
GMIPulse는 BI 지원 플랫폼을 통해 타의 추종을 불허하는 전략적 가치를 제공합니다. GMIPulse는 맞춤형 대화형 인터페이스, 정확한 데이터 및 종합적인 시장 고려 사항을 통해 경쟁이 치열한 의료 시장에서 한 발 앞서 나갈 수 있는 필수적인 도구입니다. 입니다. 지금 바로 가입하여 시장 조사 및 전략 수립 능력의 잠재력을 극대화할 수 있습니다.
LSHGlobal Market Insights Inc. offers GMIPulse, a cutting-edge, Business Intelligence (BI)-enabled platform designed to deliver the finest strategic value. GMIPulse offers an adaptable subscription service, customizable to meet your unique needs, providing comprehensive and granular market data, competitive landscape insights, and an in-depth understanding of industry ecosystems. This platform is your go-to solution for all market research needs, ensuring you stay ahead with the latest trends and technological advancements.
The healthcare industry is undergoing rapid transformation driven by technological advancements, regulatory changes, and increasing demand for innovative treatments and services. GMIPulse provides in-depth insights into the following key clusters within the healthcare industry:
The global analytical instruments market provides a critical scientific discovery tool and a QA and regulatory platform in all industries. The increase in advancement in technology, enhanced agency, and private sector R&D spending, and further utilization in pharmaceuticals, biopharmaceuticals, monitoring of health, and monitoring of the environment contributed to an observable upward trend.
The total market value for analytical instruments was reasonable valuations by 2024, with the market pricing trajectory indicating an observable compound annual growth rate (CAGR) between 2025-2034. This larger market contains several subcategories, such as chromatography, elemental analysis, immunoassay, supplies and laboratory equipment, microscopy, molecular analysis, and spectroscopy for vital analytical work in research institutions, clinical laboratories, and industrial quality control activities.. The molecular analysis segment is attractive for well-established growth opportunities from utilization patterns of increasingly high-throughput and precision methodologies in diagnostics and research.
The spectroscopy category is impressive from multiple technologies and different segments, whereas the USD 4 billion molecular spectroscopy category in 2023 is expected to exceed an estimated CAGR of 6% during 2024-2032, with specialized markets such as the USD 1.3 billion IR spectroscopy category in 2023 possibly expecting a 5% CAGR during the period 2024-2032. The sophisticated analytical methods utilize advancements in next-generation sequencing, polymerase chain reaction, and mass spectrometry to improve research capability and diagnostic accuracy.
The primary drivers of the market include increasing spending on R&D in the pharmaceutical industry, strict compliance with regulations, integration via artificial intelligence and automation, and expanding applications in clinical diagnostics and environmental testing. The industry is being enabled by miniaturization trends, greater sensitivity and accuracy of analyzers, and increasing demand for portable and point-of-care analytical solutions. Emerging manufacturing technologies, digitalization, and intelligent laboratory designs continue to transform analytical procedures and operational efficiency in all analytical instrument subcategories.
The global biotechnology industry is one of the most agile and fastest-growing sectors in modern science and medicine, fueled by advancements in genetic engineering, personalized medicine, and novel therapeutics. India's biotech industry, as reported by Invest India, is fast emerging as one of the prime drivers of economic and technological progress, and it contributes approximately 4% to the world's biotech market, with exemplary capabilities in agricultural biotechnology, biopharmaceuticals, and vaccines.
This broad market covers key subcategories such as biopharmaceuticals, bioservices, and biotechnology R&D, each covering necessary segments of scientific innovation, therapeutic development, and commercial biotechnology applications in various industries like healthcare, agriculture, and industrial biotechnology. The biopharmaceutical segment shows outstanding growth prospects with the total biopharmaceutical market worldwide pegged at USD 422.5 billion in 2024, growing from USD 453.7 billion in 2025 to USD 921.5 billion in 2034 at a CAGR of 8.2%, fueled by rising demands for targeted therapies and biologics.
Support for biotechnology R&D infrastructure shows remarkable momentum. The bioreactors market was valued at USD 10.4 billion in 2023 and will grow at 11.8% CAGR from 2024 to 2032, while the contract research organization (CRO) market will reach USD 59.8 billion in 2023 and expand at 8.1% CAGR from 2024 to 2032, supported by increasing public and private R&D spending worldwide. Each of these niches illustrates the commitment of this sector to improved scientific discovery and therapeutic development.
Growth drivers include aging populations worldwide, the rising prevalence of chronic disease, government incentives for new therapies, and significant venture capital funding into biotechnology. The industry enjoys the benefits of cutting-edge manufacturing tools, trends toward personalized medicine, and pro forma collaborations between biotech firms and large pharmaceutical companies. Gene editing, cell therapies, artificial intelligence integration, and precision medicine advances continue to transform therapeutic research and commercial biotechnology products in all biotechnology submarkets.
The global drug device combination products market is a groundbreaking union of pharmaceutical and medical device technologies, with exceptional growth fueled by rising demand for minimally invasive techniques, improved patient outcomes, and technological advancements that merge drug delivery with medical devices. The international drug device combination products market is expected to have robust growth during the next several years. It is a dynamic market that involves key subcategories like drug coated devices, drug filled devices, and therapeutic systems, each serving unique therapeutic applications in the cardiovascular, oncology, and other specialty medical procedures.
Support therapeutic systems have immense growth prospects, with the smart drug delivery systems market valued at USD 10.5 billion in 2023, which is poised to rise from USD 12 billion in 2024 to USD 48.3 billion by 2034 at a CAGR of 17%, led by increased uptake of digital health technologies. The transdermal drug delivery system market reached USD 29 billion in sales in 2022 and is expected to observe 8% CAGR from 2023 to 2032 due to a spectacular increase in cases of chronic diseases.
The major market drivers are the growing incidence of chronic disease, regulatory favor for innovative combination products, technological convergence by nanotechnology and smart materials, and growing preference for patient-focused treatment options. The industry is aided by improved therapeutic effectiveness, better patient compliance, and fewer side effects in comparison to conventional drug delivery systems. Innovative production processes, trends in personalized medicine, and collaborative business strategies between pharmaceutical firms and medical device makers continue to fuel innovation in all subcategories of drug device combinations.
The global healthcare IT market is a disruptive force in modern healthcare delivery, and it will continue to achieve unconstrained growth due to digital transformation, a requirement for interoperability, and increasing demand for data-driven healthcare solutions. The aggregate effect of AI, traditional machine learning, and deep learning can entail a total cost savings of up to $360 billion in healthcare expenditures. This wide-ranging market includes key subsegments such as artificial intelligence, health services, healthcare outsourcing, payer/provider solutions, surveillance solutions, and telehealth, which each focus on key digital transformation needs across healthcare organizations and patient care delivery systems.
The segment of artificial intelligence showcases high growth prospects in healthcare IT, with the healthcare generative AI valued at USD 1.8 billion in 2023, rising to USD 20.2 billion by the year 2032. Applications of AI cover diagnostic aid, medical imaging, and patient engagement, with the market for AI in patient engagement solutions worth USD 5 billion in 2023 and expanding at 20.1% CAGR from 2024 through 2032. These technologies use machine learning, natural language processing, and predictive analysis to improve clinical decision-making, operational effectiveness, and patient outcomes in various healthcare environments.
Major drivers of the market include regulatory compliance needs, adoption of value-based care, cybersecurity threats, and the increasing focus on patient-centric models of care delivery.
Fast digitalization was highlighted as the challenge expected to impact the global healthcare systems for the better in 2025, reflecting the healthcare sector's continuing transition from outdated systems to new technologies. The sector is currently optimistic with the adoption of cloud computing, interoperability standards, and mobile health solutions that facilitate care coordination, reduce costs, and improve access across all health IT sectors.
The medical devices market is one of the most innovative and dynamic healthcare sectors, with intense growth fueled by technology development, aging populations, and rising incidence of chronic conditions necessitating advanced medical interventions. The global medical device market is expected to witness steady growth, with worldwide yearly sales set to grow more than 5% annually, reaching nearly USD 800 billion by the year 2030. This has accelerated the demand for advanced devices and data-driven health care services, the prevalence of lifestyle-related diseases, and opportunities in growth markets, mainly in China and India. The cardiovascular devices market has huge upside potential. The global market for cardiovascular devices is expected to reach USD 7.5 billion in 2024 and is projected to grow at a CAGR of 13.5% from 2025-2034 as demand for minimally invasive surgeries continues to grow.
The wearable medical devices market demonstrates outstanding growth, with the market value at USD 120.1 billion in 2024 and is anticipated to rise to USD 543.9 billion by 2034, with a CAGR of 16.5% over the forecast period. The highly developed healthcare devices make use of technology for real-time monitoring, diagnostics, and treatment purposes in various specialties in medicine. Major market drivers are aging population transitions in demographics, rising incidence of chronic diseases, technology assimilation in the form of IoT and AI functions, and growing healthcare infrastructure in developing economies. The industry is supported by regulatory convergence, adoption of digital health, personalized medicine shifts, and value-based healthcare models driven by enhanced patient outcomes. Materials science innovation, miniaturization technologies, and connectivity solutions continue to transform device capabilities and patient accessibility in all medical device subcategories.
The global medical services sector is a fundamental pillar to the healthcare infrastructure and is currently going through unprecedented growth driven by ageing populations, advancing technological capabilities, and increased demand for comprehensive patient care within the frameworks of a vast array of service delivery models. Healthcare profit pools are increase at 4% CAGR from $654 billion in 2021 to $790 billion by 2026. This growth will be substantially driven by an increased shift toward Medicare as the over-65 population is projected to rise by 3% annually over the forecast period. This large market covers key subcategories, such as diagnostic services, inpatient and outpatient services, laboratory services, long-term care services, and surgical services, each capturing key healthcare delivery needs across a range of patient populations and care settings.
The diagnostic services segment exhibits good growth momentum, and it is reported that specialty areas are experiencing incredible growth. The market for ophthalmology diagnostics had an estimated size of USD 8.7 billion in 2022 and is anticipated to see a CAGR of 4.4% between 2023 and 2032 attributed to the increasing prevalence of eye diseases. Laboratory services continue to be the backbone diagnostic of healthcare system, pathology laboratory equipment market size was USD 33 billion in 2022 and is projected to be USD 75 billion by 2032 due to the increasing incidence of chronic disease. Complementing diagnostic features, the diagnostics segment of the medical display market accounted for USD 2.2 billion revenue in 2022 due to the central position played by it in healthcare wherein proper diagnosis is imperative for patient treatment.
Major drivers in the market are demographic trends to aging populations, rising chronic disease burden, technology integration in the form of digital health solutions, and growing healthcare access in emerging markets. The industry is aided by telemedicine implementation, AI-based diagnostic solutions, and value-based care platforms focusing on patient outcomes. Regulatory compliance, quality standards and health workforce development remains critical to optimize service delivery in all medical service sub-designate.
The global pharmaceuticals business is one of the most crucial and fastest-growing healthcare industries, fueled by aging populations, rising rates of chronic diseases, and ongoing innovation in drug formulation and manufacturing technology. India's pharmaceutical industry was worth USD 50 billion in FY 2023-24, with USD 23.5 billion representing domestic consumption and USD 26.5 billion in exports, as per government statistics. This large market is comprised of several distinct categories and market segments, including active pharmaceutical ingredients, clinical nutrition, medicines for specific diseases, drug delivery systems, finished drugs, pharmaceutical excipients, manufacturing processes, and vaccines; all of which are critical healthcare and regulatory needs in global markets.
The active pharmaceutical ingredients segment is the backbone of pharmaceutical production, where the market was worth more than USD 228.5 billion in 2022 and is projected to grow at over 6.5% CAGR during the period from 2023 to 2032 due to expanding demand for drugs and treatment of rare diseases. Targeted segments of APIs exhibit impressive growth, such as high potency active pharmaceutical ingredients market worth USD 27.1 billion in 2024 and projected to advance at a 8.8% CAGR during 2025-2034 and small molecule API market worth USD 194.7 billion in 2024 and projected to advance at a 5.8% CAGR during 2025-2034, with escalating incidence of chronic diseases.
Major drivers for the market are increasing healthcare spending, regulatory convergence globally, patent losses giving rise to generic opportunities, and technological innovation in precision medicine, biologics, and personalized therapeutics. The overall sector benefits from substantial research and development investment, continued growth in contract manufacturing, and expanded market access in growing emerging economies. The digitization of the sector and the incorporation of AI-assisted drug discovery and next generation manufacturing technologies are fundamentally changing the efficacy and efficiency of the development, manufacturing, and regulatory compliance of ALL categories and market segments in pharmaceutical development and manufacturing.
GMIPulse by Global Market Insights Inc. offers unparalleled strategic value through its BI-enabled platform. With its customizable and interactive interface, accurate data, and comprehensive market insights, GMIPulse is your essential tool for staying ahead in the competitive healthcare market landscape. Subscribe today to unlock the full potential of your market research and strategic planning capabilities.